
    
      STUDY DESIGN: An observational, multicenter, cross-sectional study. A total of 20
      diabetologist from four Croatian regions will recruit up to ten subjects of both sexes from
      May 2018 till the end of May 2019, diagnosed with type 2 diabetes mellitus at least one year
      prior to study entry, aged ≥40 years, with only basal insulin in therapy and with clinical
      suspicion of hypoglycemia or with disproportion in actual glycaemia and hemoglobin A1c
      findings. Sociodemographic, laboratory (HbA1c, fasting and postprandial glucose, total
      cholesterol, and high density cholesterol, and low density cholesterol, triglyceride and
      serum creatinine) and habits data will be collected.

      SETTING: Totally 100 of patients will be included. At diabetologist office each patient wear
      the device (iPro™2 Medtronic) subcutaneously for up to 7-days and return it to the office for
      download. Patients only see the CGM data after it's been analyzed by the healthcare
      professional. A CGM device is to be set and take off by the diabetologist. Before the study
      start all diabetologist who are not familiar to the method will have a short education. Study
      period is seven days and includes screening before study entry and two visits. On Day 1,
      after screening and signing the informed consent, the CGM device is applied. Patient is
      instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating,
      physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is
      uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing
      CGM.
    
  